The Atopic Dermatitis and Novel Agents Comparative ... This trend was driven by upadacitinib compared with dupilumab (RR, 2.15; 95% CI, 1.01-4.56) whereas no significant difference in serious ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

The drug is also being studied in other immune-mediated diseases – phase 3 trials of upadacitinib in atopic dermatitis, psoriatic arthritis, Crohn's disease, and ulcerative colitis are ongoing ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

Infections Higher With JAK Inhibitors in Eczema Study A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac’s ...

Atopic dermatitis, commonly referred to as eczema, has been a part of my life for as long as I can remember. For many years, I didn't even know what it was called. My journey with this condition ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...